Loading…
Loading…
Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.
Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment for acute kidney injury Integrated technology helps hospital intensive care teams deliver complex treatment simply and efficiently BAD HOMBURG, Germany, Oct. 21, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney injury (AKI). multiFiltratePRO's integrated technology eliminates the need for separate citrate and calcium pumps, and automatically adjusts as treatment conditions change, making complex treatment easier for hospital intensive care teams to manage.
LAS VEGAS--(BUSINESS WIRE)--flyExclusive, Inc. (NYSE American: FLYX), one of the nation's largest private jet operators, today announced that Fly Alliance has agreed to replace its existing flight management system across its entire operation with Contrails FMS, flyExclusive's free, AI-powered aviation operating platform.The announcement, made at NBAA-BACE 2026, represents a significant milestone for Contrails FMS and introduces a new approach to aviation technology: providing operators with adv.
BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the American Society of Nephrology's (ASN) Kidney Week 2026, taking place October 21-25 in Denver, Colorado.
FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.
FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.
Fresenius Medical Care AG and Co. KGaA (NYSE: FMS - Get Free Report) has received an average recommendation of "Reduce" from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell rating and six have given a hold rating to the company.
Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expected to result in related one-time costs in Q3 2026 treated as a special item BAD HOMBURG, Germany, Sept. 25, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced refinements to its China commercial strategy to support long-term growth and strengthen its market position through a more localized portfolio, increased commercialization of locally relevant innovation and a focused go-to-market approach.